CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source.
This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Advances in CRISPR-Cas systems for human diseasesVijai Singh
2. Advances in CRISPR -Cas systems for human bacterial disease
Indra Mani
3. Advances in CRISPR-Cas systems for gut microbiome
Indra Mani
4. Recent progress in CRISPR -Cas systems for human viral disease
Vijai Singh
5. Recent development in CRISPR -Cas systems for human protozoan diseases
ABHISHEKA BANSAL, Utkarsh Gangwar, Himashree Choudhury and Risha Shameem
6. Advances in CRISPR -Cas systems for fungal infections
Ajay Kumar I
7. Advances in CRISPR-Cas systems based cell and gene therapy
Aparna Jayachandran and Arpita Poddar
8. Advances in CRISPR-Cas systems for epigenetics
Mustafeez Mujtaba Babar, Mahnoor Ilyas, Alvina Gul and Jayakumar Rajadas
9. Current progress in CRISPR -Cas systems for cancer
Mustafeez Mujtaba Babar, Hajra Ali, Hunaiza Fatima, Alvina Gul and Jayakumar Rajadas
10. Current progress in CRISPR -Cas systems for autoimmune diseases
Ajay Kumar I
11. Advances in CRISPR -Cas systems for blood disorders
Deepak balaji Thimiri govindaraj and Mutsa Monica Takundwa
